A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
NCT02927340
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG:
Lorlatinib
Sponsor
Massachusetts General Hospital